What Does Galapagos (GLPG) Do? - Stock Outlook, Earnings, Market Cap, Related Stocks & Headquarters Summary
A Belgian biotech leader holding €3.3 billion in cash that exceeds its market cap, driving a turnaround in the cancer and autoimmune disease markets through an innovative CAR-T cell therapy platform that can be manufactured in just 7 days.
Subscribe🏢 What kind of company is Galapagos?
Galapagos (Galapagos NV, GLPG) is a global biotechnology company founded in 1999 and headquartered in Mechelen, Belgium. Once known for a major partnership with Gilead Sciences and its rheumatoid arthritis treatment Jyseleca, it has recently undergone a full business restructuring to transform into a next-generation cell therapy specialist. In particular, in the field of CAR-T therapy—where a patient's blood is collected and immune cells are engineered to attack cancer cells before being reinfused—the company is leading innovation in the market with its "decentralized manufacturing model," which enables production near hospitals and dramatically shortens processing times.
💰 How does it make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Collaboration & Royalty Revenue (Gilead, etc.) | About 90% or more | Technology fees and residual royalties received from partners such as Gilead Sciences |
| Other Services & Products | Less than 10% | Revenue from research & development data provision and other bio-related services |
Galapagos's revenue structure is currently in a transitional period. Having divested the rights to its former flagship product Jyseleca and restructured its exclusive partnership with Gilead, the bulk of revenue now comes from milestones and royalties under legacy contracts rather than short-term product sales. However, with massive cash assets of approximately €3.3 billion (around KRW 4.8 trillion) as of 2025, the company has a unique financial position that allows it to fully commit to the clinical development and commercialization of its proprietary CAR-T pipeline (including GLPG5101), regardless of the revenue gap.
📐 Market Cap and Corporate Scale
The market cap stands at $1.8B, roughly About 1% of Samsung Electronics's market cap. The company employs 452 people people.
Galapagos is a biotech company with a market cap of $1.8B, approximately About 1% of Samsung Electronics's market cap. The company's market cap has been trading below its net cash holdings, exhibiting the classic profile of a "cash-rich" company. Around 452 people specialized personnel are devoted to innovative drug development from European hubs in Belgium and the Netherlands.
Galapagos Outlook and Stock Performance
The forward outlook hinges on the clinical success and commercial uptake of its decentralized CAR-T manufacturing platform. Recording revenue of $1.3B as of 2025, the company is undergoing structural improvements, and its capability to manufacture CAR-T therapy within 7 days is an overwhelming advantage over competitors whose processes typically take 3 to 4 weeks. If key clinical data in blood cancers and autoimmune diseases from 2026 onward come in positive, the value of its cash holdings could be reassessed, and a strong turnaround in $5.96 and 11.5% would be expected. The repricing of its relationship with Gilead—regaining independent global commercialization rights—is also a positive long-term variable.
⚔️ Core Competitive Strengths and Risks
On top of a "safety net" of cash holdings exceeding the share price, the company has installed a powerful growth engine: CAR-T manufacturing innovation.
💪 Core Competitive Strengths
⚠️ Core Risks
Competitors and Related Stocks (Beneficiaries)
Galapagos's key competitors include CAR-T therapy market leaders Gilead Sciences (GILD), Novartis (NVS), and Bristol-Myers Squibb (BMY). On the innovative manufacturing platform side, the company is also compared with contract development and manufacturing organizations (CDMOs) such as Lonza. Related stocks include the European biotech sector and cell therapy ETF (IDNA).
✅ Investor Checklist
If you are looking to invest in the value of cash assets combined with the innovation of next-generation cell therapy, you should verify the following key elements.
| Checklist | What to Verify | Current Status |
|---|---|---|
| Description | Status | |
| Net Cash Assets | Check whether the stock is undervalued—trading below the value of the company's cash holdings. | Healthy |
| GLPG5101 Clinical Data | Confirm whether the core CAR-T pipeline's efficacy and safety data are superior to competing drugs. | In Progress |
| Additional Partnerships & M&A | Monitor whether new acquisitions of promising biotechs or new co-development agreements emerge on the back of abundant cash. | Healthy |
Note that biotech stocks experience extreme volatility around clinical announcements, and companies like Galapagos that have gone through restructuring may take time to numerically demonstrate management's execution capabilities.
Galapagos is a company that has weathered the trials of failure and returned wielding even stronger weapons. The fact that ample cash on hand allows it to pursue innovation without haste is a great comfort to investors, and if its disruptive 7-day CAR-T manufacturing innovation succeeds, Galapagos could once again be the protagonist that reshapes the biotech market landscape.
Check Galapagos's real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
1-Year Price Performance
Analyst Consensus
52-Week Price Range⚔️ Core Competitive Strengths and Risks
On top of a "safety net" of cash holdings exceeding the share price, the company has installed a powerful growth engine: CAR-T manufacturing innovation.
💪 Core Competitive Strengths
⚠️ Core Risks
Competitors and Related Stocks (Beneficiaries)
Galapagos's key competitors include CAR-T therapy market leaders Gilead Sciences (GILD), Novartis (NVS), and Bristol-Myers Squibb (BMY). On the innovative manufacturing platform side, the company is also compared with contract development and manufacturing organizations (CDMOs) such as Lonza. Related stocks include the European biotech sector and cell therapy ETF (IDNA).
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences Inc | $143.72 | -0.8% | $178.2B | - | 15.1 | -20.57% | 2.26% |
| NVS | Novartis AG ADR | $137.16 | -0.2% | $251.1B | 20.7 | 6.0 | 30.56% | 3.23% |
| BMY | Bristol-Myers Squibb Co | $63.64 | -0.2% | $130.0B | 14.0 | 5.8 | 46.7% | 3.67% |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 ARWR | Arrowhead Pharmaceuticals Inc | $82.85 | +0.1% | $11.7B | - | 25.1 | -64.78% | - |
| ALNY | Alnylam Pharmaceuticals Inc | $248.67 | +0.5% | $33.3B | 42.0 | 24.6 | 100.7% | - |
 RARE | Ultragenyx Pharmaceutical Inc | $14.30 | -0.7% | $1.4B | - | - | -656.54% | - |
✅ Investor Checklist
If you are looking to invest in the value of cash assets combined with the innovation of next-generation cell therapy, you should verify the following key elements.
| Checklist | What to Verify | Current Status |
|---|---|---|
| Description | Status | |
| Net Cash Assets | Check whether the stock is undervalued—trading below the value of the company's cash holdings. | Healthy |
| GLPG5101 Clinical Data | Confirm whether the core CAR-T pipeline's efficacy and safety data are superior to competing drugs. | In Progress |
| Additional Partnerships & M&A | Monitor whether new acquisitions of promising biotechs or new co-development agreements emerge on the back of abundant cash. | Healthy |
Note that biotech stocks experience extreme volatility around clinical announcements, and companies like Galapagos that have gone through restructuring may take time to numerically demonstrate management's execution capabilities.
Galapagos is a company that has weathered the trials of failure and returned wielding even stronger weapons. The fact that ample cash on hand allows it to pursue innovation without haste is a great comfort to investors, and if its disruptive 7-day CAR-T manufacturing innovation succeeds, Galapagos could once again be the protagonist that reshapes the biotech market landscape.
Check Galapagos's real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free